Presentation is loading. Please wait.

Presentation is loading. Please wait.

NAPLES II Novel Approaches for Preventing or Limiting Event Study Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction.

Published byAlejandro Stokes Modified over 10 years ago

Similar presentations

Presentation on theme: "NAPLES II Novel Approaches for Preventing or Limiting Event Study Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction."— Presentation transcript:

1 NAPLES II Novel Approaches for Preventing or Limiting Event Study Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction Carlo Briguori, MD, PhD Laboratoy of Interventional Cardiology Clinica Mediterranea, Naples - Italy

2 I, Carlo Briguori DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. Disclosure Statement of Financial Interest

3 Periprocedural non-Q MI is a frequent and prognostically important complication of PCI 1. The available data suggest that statin prevent periprocedural MI 2-3 Statin administration should be started at least 3 - 7 days before the procedure 2 It is unknown whether a single, high (80 mg) loading (within 24 hours) dose of atorvastatin may reduce the rate of periprocedural MI. Background 1 Hermann J. Eur Heart J 2005; 25: 2493 2 Pasceri V. et al.. Circulation 2004;110:674-8 3 Briguori C et al. Eur Heart J 2004;25:1822-8

4 Pleiotropic effects

5 An immediate significant effect of just a single dose of statin has been previously reported Ostadal et al. demonstrated that a single dose of cerivastatin at the time of admission of patients with unstable angina or non-ST elevation MI positively influences the inflammatory parameters CRP and interleukin-6 at 24 hours ( Mol Cell Biochem 2003;246:45-50) Romano et al. described that a 24-h treatment with lovastatin and simvastatin induces inhibition of monocyte chemotactic protein-1 (MCP-1) synthesis in mononuclear and endothelial cells in vitro ( Lab Invest 2000;80:1095-1100) Statins indeed have beneficial effects on endothelial function by a rapid increase in nitric oxide bioavailability; this effect has been observed as early as 3 hours following statin administration (Laufs et al. Circulation 1998;97:1129- 1135 ) Background

6 To assess whether a single, high (80 mg), loading (within 24 hours) dose of atorvastatin is effective in preventing elevation of biomarkers of MI following elective coronary stent implantation. Purpose

7 NAPLES II DESIGN: Prospective, randomized, double-arm, 2-center clinical, spontaneous study Elective PCI in de novo lesions, in native coronary artery No statin therapy Biomarker negative Atorvastatin 80 mg No atorvastatin ASA Clopidogrel (loading dose 300 mg the day before procedure) Elective PCI CKMB >3X ULN

8 Hypothesis: Riduction in the primary endpoint from 15% in the Control group to 8% in the Atorvastatin group 1-2 Sample size : A total of 650 patients (325 each group) will be necessary to gave the study 80% power and a significance level <0.05 Sample size 1 Pasceri V. et al.. Circulation 2004;110:674-8 2 Briguori C et al. Eur Heart J 2004;25:1822-8

9 Inclusion criteria Age 18 y De novo lesion in a native coronary artery Elective PCI Normal cardiac biomarkers No statin therapy

10 Exclusion criteria Primary or rescue PCI ACS with elevated cardiac markers Pregnancy Restenotic lesion SVG or LIMA treatment Active statin therapy History of intolerance to statin

11 Non-Q wave MI: CKMB 3X ULN Q wave MI: CKMB 2X ULN with new significant Q waves in 2 contiguous leads Definitions Thygesen K et al. Eur Heart J 2007;28:2525-38.8

12 Patients undergoing coornary angiography Jan 2005-Jan 2009 assessed for eligibility (n=1385) Excluded (n=37) 9 withdrew consent 28 did not meet the inclusion criteria 1348 patients randomized 676 allocated to Atorvastatin group 676 received the allocated treatment 672 allocated to Control group 672 received the allocated treatment 338 patients included 330 patients included 338 excluded because: 155 had coronary angiography alone and not PCI 98 had PCI for ISR and/or on a bypass vessel 80 were referred for elective CABG 5 were lost at follow-up 342 excluded because: 174 had coronary angiography alone and not PCI 91 had PCI for ISR and/or on a bypass vessel 71 were referred for eventual CABG 6 were lost at follow-up

13 Clinical Characteristics Atorvastatin Group (N=338) Control Group (N=330) Age, yrs (mean SD)64 965 10 Male, %266 (78.7%)263 (79.7%) BMI (kg/m 2 ) 27.8 3.827.4 3.5 Symptoms Asymptomatic Stable angina Unstable angina 45 (13.3%) 285 (84.3% 8 (2.4%) 34 (10.3%) 288 (87.3%) 8 (2.4%) Family history for CAD101 (30%)112 (34%) Diabetes mellitus130 (38.6%)121 (36.8%) Hypertension, %131 (78%)125 (74.9%) Current smoker, %79 (24%)66 (20%) Prior MI, %113 (33.4%)97 (29.4%) Prior PCI*, %41 (12.1%)31 (9.4%) Prior CABG, %24 (7.1%)27 (8.1%) LVEF, % (mean SD)55.7 9.555.5 9.9 -blockers 130 (38.5%)129 (39.1%) * Percutaneous intervention performed in a different vessel and/or lesion.

14 Biochemical Characteristics Atorvastatin Group (N=338) Control Group (N=330) Serum creatinine, median (IQR) GFR (ml/min/1.73 m 2 ) GFR < 60 1.16 (1.00-1.32) 65 17 124 (36.6%) 1.18 (1.00-1.35) 64 19 140 (42.4%) Fibrinogen, mg/dL 379 123363 100 Lipid, mg/dL Total Cholesterol LDL-C HDL-C Tryglicerides 211 46 126 35 48 11 159 88 210 42 129 37 48 12 151 88

15 Rate of high CRP 0 10 20 30 40 50 Atorvastatin group (n= 338) Control group (n = 330) p = 0.31 25.4 29.4 %

16 Angiographic & Procedural Characteristics Atorvastatin Group (N=338) Control Group (N=330) Distribution of CAD 1-vessel 2-vessel 3-vessel 128 (37.9%) 121 (35.8%) 89 (26.3%) 125 (37.9%) 117 (35.5%) 88 (26.6%) Target vessel LAD Cx RCA LM 371 186 (50.1%) 72 (19.5%) 107 (28.8%) 6 (1.6%) 366 185 (50.5%) 71 (19.4%) 105 (28.5%) 6 (1.6%) Lesion site Ostial Proximal Mid Distal 436 46 (10.7%) 193 (44.2%) 161 (36.9%) 35 (8.2%) 426 47 (11%) 189 (44.4%) 172 (40.4%) 18 (4.2%)

17 Angiographic & Procedural Characteristics Atorvastatin Group (N=338) Control Group (N=330) Multivessel stenting37 (11%)33 (10%) Direct stenting96 (28.5%)100 (30.3%) Atherectomy5 (1.5%)7 (2.1%) No. treated vessel/patient 1.1 0.51.1 0.3 No. treated lesion/patient 1.3 0.6 CTO64 (18.9%)59 (17.9%) Thrombus6 (1.7%)9 (2.7%) Complex (B2/C) lesions173 (51.3%)177 (53.7%) Bifurcation lesions56 (16.7%)55 (16.6%) GP IIb/IIIa inhibitors43 (12.7%)46 (13.6%) Calcified lesions80 (23.7%)88 (26.8%)

18 Angiographic & Procedural Characteristics Atorvastatin Group (N=338) Control Group (N=330) Preprocedural QCA RVD, mm MLD, mm DS, % Lesion length, mm 3.16 0.62 0.51 0.44 85 12 18 10 3.23 0.59 0.51 0.40 84 13 19 8 Postprocedural QCA RVD, mm MLD, mm DS, % 3.36 0.61 3.34 0.61 2 6 3.41 0.58 3.37 0.60 2 3 Stent length, mm 30 16 Max inflation pressure, atm 15 4 TIMI flow grade pre 0/1 2/3 54 (16%) 284 (84%) 54 (16.5%) 276 (83.5%) TIMI flow grade post 0/1 2/3 1 (0.3%) 337 (99.7%) 0 330 (100%) BA ratio 1.05 0.121.03 0.09

19 Angiographic Complications Atorvastatin Group (N=338) Control Group (N=330) P Major dissection1 (0.59%)3 (0.90%)0.68 Abrupt closure1 (0.29%)00.48 Slow/No reflow2 (0.59%)8 (2.40%)0.06 Thrombus formation2 (0.59%)00.50 Side branch closure/compromise5 (1.48%)7 (2.12%)0.57 Distal embolization2 (0.59%)2 (0.60%)1.00 Perforation2 (0.59%)2 (0.60%)1.00 Any of the above16 (4.7%)22 (6.6%)0.31

20 CKMB >3X ULN 0 2 4 6 8 10 12 14 16 Atorvastatin group (n= 338) Control group (n = 330) p = 0.014 (OR = 0.56; 95% CI = 0.35-0.89) % 9.5 15.8

21 cTnI >3X ULN 0 5 10 15 20 25 30 35 40 26.6 39.1 Atorvastatin group (n= 338) Control group (n = 330 ) p <0.001 (OR = 0.56; 95% CI = 0.40-0.78) %

22 28/252 35/233 11.1 15 4/86 16/97 4.6 16.5 0 2 4 6 8 10 12 14 16 18 Atorvastatin group (n= 338) Control group (n = 330) p = 0.18p = 0.016 CKMB 3X ULN & CRP Normal CRPHigh CRP %

23 31 39.5 15.1 38.1 0 5 10 15 20 25 30 35 40 Normal CRPHigh CRP Atorvastatin group (n= 338) Control group (n = 330 ) p = 0.056 p = 0.002 TnI 3X ULN & CRP % 78/252 92/233 13/86 37/97

24 In-hospital outcome Atorvastatin Group (N=338) Control Group (N=330) P value Death1 (0.3%)0NS MI33 (9.8%)52 (15.8%)0.014 Q-wave MI1 (0.3%)0NS Non Q-wave MI32 (9.5%)52 (15.8%)0.014 Unplanned revasc00- Stent thrombosis2 (0.58%)1 (0.30%)0.57 Composite34 (10%)52 (15.7%)0.029

25 Conclusions A single, high (80 mg) loading (within 24 hours) dose of atorvastatin reduces the incidence of periprocedural non Q wave MI in elective PCI. This cardioprotective effect seems to be more pronounced in patients with high CRP level at baseline

26 Naples II trial group Clinica Mediterranea, Naples Cath Lab group: C. Briguori A. Focaccio G. Visconti ICU group: B. Ricciardelli B. Golia M.T. Librera

27 Naples II trial group ICU group: A. Castelli M. Mongiardo Study coordinator A. Ferrari San Raffaele Hospital, Milan Cath Lab group: A. Colombo M. Montorfano A. Chieffo

Download ppt "NAPLES II Novel Approaches for Preventing or Limiting Event Study Impact of a Single High Loading Dose of Atorvastatin on Periprocedural Myocardial Infarction."

Similar presentations

Introduction: In the setting of a suspected acute coronary syndrome (ACS), aspirin (ASA) is the primary treatment used for platelet inhibition. However,

Introduction: In the setting of a suspected acute coronary syndrome (ACS), aspirin (ASA) is the primary treatment used for platelet inhibition. However,
Patient Oriented Therapy Non STE ACS

Patient Oriented Therapy Non STE ACS
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of.

Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of.
August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
NAPLES Novel Approaches for Preventing or Limiting Event Study Randomised Comparison of Bivalirudin Monotherapy versus Unfractionated Heparin plus Tirofiban.

NAPLES Novel Approaches for Preventing or Limiting Event Study Randomised Comparison of Bivalirudin Monotherapy versus Unfractionated Heparin plus Tirofiban.
Seoul National University Hospital CILON-T Late Breaking Trial : Randomized prospective trial of dual vs. triple antiplatelet therapy after DES implantation.

Seoul National University Hospital CILON-T Late Breaking Trial : Randomized prospective trial of dual vs. triple antiplatelet therapy after DES implantation.
1  1 =.

1  1 =.
MEND-CABG II ACC08 LBCT JHA, 1 John H. Alexander, MD, MS, FACC On behalf of the MEND-CABG II Investigators A Randomized, Double-blind, Placebo-controlled,

MEND-CABG II ACC08 LBCT JHA, 1 John H. Alexander, MD, MS, FACC On behalf of the MEND-CABG II Investigators A Randomized, Double-blind, Placebo-controlled,
The ABC’s of the AHA/ACC Prevention Guidelines

The ABC’s of the AHA/ACC Prevention Guidelines
Carlo Briguori, MD, FACC, FSCAI Clinica Mediterranea, Naples, Italy

Carlo Briguori, MD, FACC, FSCAI Clinica Mediterranea, Naples, Italy
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.

GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.

OPTIMIZE: A Prospective, Randomized Trial of 3 Months Versus 12 Months of Dual Antiplatelet Therapy with the Endeavor Zotarolimus-Eluting Stent Fausto.
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.

Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
Local improvement following national clinical audit workshops Auditing heart attacks Saving lives Dr Andrew Wragg Barts Health.

Local improvement following national clinical audit workshops Auditing heart attacks Saving lives Dr Andrew Wragg Barts Health.
Early assessment of myocardial injury by joint measurement of TnT-hs and Copeptin (1) J. Teixeira, (2) P. Wotquenne, (2) V. D’Orio, (3) D. Gruson, (1)

Early assessment of myocardial injury by joint measurement of TnT-hs and Copeptin (1) J. Teixeira, (2) P. Wotquenne, (2) V. D’Orio, (3) D. Gruson, (1)
Partial Products. Category 1 1 x 3-digit problems.

Partial Products. Category 1 1 x 3-digit problems.
3-1. 3-2 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients treated with Percutaneous Coronary Intervention. Relationship with Gene.

Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients treated with Percutaneous Coronary Intervention. Relationship with Gene.
PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.

PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.

Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.

Similar presentations

Ads by Google